

Global NK1/NK3 Receptor Antagonists Market Growth 2025-2031

<https://marketpublishers.com/r/G97DAD25310BEN.html>

Date: August 2025

Pages: 132

Price: US\$ 3,660.00 (Single User License)

ID: G97DAD25310BEN

Abstracts

The global NK1/NK3 Receptor Antagonists market size is predicted to grow from US\$ 1028 million in 2025 to US\$ 1460 million in 2031; it is expected to grow at a CAGR of 6.0% from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

NK1/NK3 receptor antagonists comprise three categories: NK-1 receptor antagonists, NK-3 receptor antagonists, and dual antagonists that target both receptors. NK-1 receptor antagonists block the binding of substance P to the NK1 receptor and are primarily used to prevent and treat chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. NK-3 receptor antagonists inhibit neurokinin B signaling via the NK3 receptor and are under investigation for treating vasomotor symptoms such as menopausal hot flashes. Dual antagonists act on both NK1 and NK3 receptors, offering combined antiemetic and central neuroregulatory effects, and are being explored for indications like menopausal syndrome and depression.

United States market for NK1/NK3 Receptor Antagonists is estimated to increase from US\$ million in 2024 to US\$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for NK1/NK3 Receptor Antagonists is estimated to increase from US\$ million in 2024 to US\$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for NK1/NK3 Receptor Antagonists is estimated to increase from US\$ million in 2024 to US\$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key NK1/NK3 Receptor Antagonists players cover Merck, Helsinn Healthcare, TerSera Therapeutics, Astellas, Bayer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LP Information, Inc. (LPI) ' newest research report, the "NK1/NK3 Receptor Antagonists Industry Forecast" looks at past sales and reviews total world NK1/NK3 Receptor Antagonists sales in 2024, providing a comprehensive analysis by region and market sector of projected NK1/NK3 Receptor Antagonists sales for 2025 through 2031. With NK1/NK3 Receptor Antagonists sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world NK1/NK3 Receptor Antagonists industry.

This Insight Report provides a comprehensive analysis of the global NK1/NK3 Receptor Antagonists landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on NK1/NK3 Receptor Antagonists portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global NK1/NK3 Receptor Antagonists market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for NK1/NK3 Receptor Antagonists and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global NK1/NK3 Receptor Antagonists.

This report presents a comprehensive overview, market shares, and growth opportunities of NK1/NK3 Receptor Antagonists market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

NK1 Receptor Antagonist

NK3 Receptor Antagonist

Dual Antagonist

Segmentation by Application:

Hospital

Specialty Clinic

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Merck

Helsinn Healthcare

TerSera Therapeutics

Astellas

Bayer

Heron Therapeutics

Glenmark

Torrent Pharmaceuticals

Fresenius Kabi

Chia Tai Tianqing Pharmaceutical

Qilu Pharmaceutical

Jiangsu Hengrui Pharmaceuticals

Beijing Sihuan Pharmaceutical

Yichang Humanwell Pharmaceutical

Hansoh Pharma

Luoxin Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global NK1/NK3 Receptor Antagonists market?

What factors are driving NK1/NK3 Receptor Antagonists market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do NK1/NK3 Receptor Antagonists market opportunities vary by end market size?

How does NK1/NK3 Receptor Antagonists break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global NK1/NK3 Receptor Antagonists Annual Sales 2020-2031
 - 2.1.2 World Current & Future Analysis for NK1/NK3 Receptor Antagonists by Geographic Region, 2020, 2024 & 2031
 - 2.1.3 World Current & Future Analysis for NK1/NK3 Receptor Antagonists by Country/Region, 2020, 2024 & 2031
- 2.2 NK1/NK3 Receptor Antagonists Segment by Type
 - 2.2.1 NK1 Receptor Antagonist
 - 2.2.2 NK3 Receptor Antagonist
 - 2.2.3 Dual Antagonist
- 2.3 NK1/NK3 Receptor Antagonists Sales by Type
 - 2.3.1 Global NK1/NK3 Receptor Antagonists Sales Market Share by Type (2020-2025)
 - 2.3.2 Global NK1/NK3 Receptor Antagonists Revenue and Market Share by Type (2020-2025)
 - 2.3.3 Global NK1/NK3 Receptor Antagonists Sale Price by Type (2020-2025)
- 2.4 NK1/NK3 Receptor Antagonists Segment by Application
 - 2.4.1 Hospital
 - 2.4.2 Specialty Clinic
- 2.5 NK1/NK3 Receptor Antagonists Sales by Application
 - 2.5.1 Global NK1/NK3 Receptor Antagonists Sale Market Share by Application (2020-2025)
 - 2.5.2 Global NK1/NK3 Receptor Antagonists Revenue and Market Share by Application (2020-2025)
 - 2.5.3 Global NK1/NK3 Receptor Antagonists Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global NK1/NK3 Receptor Antagonists Breakdown Data by Company

3.1.1 Global NK1/NK3 Receptor Antagonists Annual Sales by Company (2020-2025)

3.1.2 Global NK1/NK3 Receptor Antagonists Sales Market Share by Company (2020-2025)

3.2 Global NK1/NK3 Receptor Antagonists Annual Revenue by Company (2020-2025)

3.2.1 Global NK1/NK3 Receptor Antagonists Revenue by Company (2020-2025)

3.2.2 Global NK1/NK3 Receptor Antagonists Revenue Market Share by Company (2020-2025)

3.3 Global NK1/NK3 Receptor Antagonists Sale Price by Company

3.4 Key Manufacturers NK1/NK3 Receptor Antagonists Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers NK1/NK3 Receptor Antagonists Product Location Distribution

3.4.2 Players NK1/NK3 Receptor Antagonists Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR NK1/NK3 RECEPTOR ANTAGONISTS BY GEOGRAPHIC REGION

4.1 World Historic NK1/NK3 Receptor Antagonists Market Size by Geographic Region (2020-2025)

4.1.1 Global NK1/NK3 Receptor Antagonists Annual Sales by Geographic Region (2020-2025)

4.1.2 Global NK1/NK3 Receptor Antagonists Annual Revenue by Geographic Region (2020-2025)

4.2 World Historic NK1/NK3 Receptor Antagonists Market Size by Country/Region (2020-2025)

4.2.1 Global NK1/NK3 Receptor Antagonists Annual Sales by Country/Region (2020-2025)

4.2.2 Global NK1/NK3 Receptor Antagonists Annual Revenue by Country/Region (2020-2025)

4.3 Americas NK1/NK3 Receptor Antagonists Sales Growth

4.4 APAC NK1/NK3 Receptor Antagonists Sales Growth

4.5 Europe NK1/NK3 Receptor Antagonists Sales Growth

4.6 Middle East & Africa NK1/NK3 Receptor Antagonists Sales Growth

5 AMERICAS

5.1 Americas NK1/NK3 Receptor Antagonists Sales by Country

5.1.1 Americas NK1/NK3 Receptor Antagonists Sales by Country (2020-2025)

5.1.2 Americas NK1/NK3 Receptor Antagonists Revenue by Country (2020-2025)

5.2 Americas NK1/NK3 Receptor Antagonists Sales by Type (2020-2025)

5.3 Americas NK1/NK3 Receptor Antagonists Sales by Application (2020-2025)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC NK1/NK3 Receptor Antagonists Sales by Region

6.1.1 APAC NK1/NK3 Receptor Antagonists Sales by Region (2020-2025)

6.1.2 APAC NK1/NK3 Receptor Antagonists Revenue by Region (2020-2025)

6.2 APAC NK1/NK3 Receptor Antagonists Sales by Type (2020-2025)

6.3 APAC NK1/NK3 Receptor Antagonists Sales by Application (2020-2025)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe NK1/NK3 Receptor Antagonists by Country

7.1.1 Europe NK1/NK3 Receptor Antagonists Sales by Country (2020-2025)

7.1.2 Europe NK1/NK3 Receptor Antagonists Revenue by Country (2020-2025)

7.2 Europe NK1/NK3 Receptor Antagonists Sales by Type (2020-2025)

7.3 Europe NK1/NK3 Receptor Antagonists Sales by Application (2020-2025)

7.4 Germany

7.5 France

- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa NK1/NK3 Receptor Antagonists by Country
 - 8.1.1 Middle East & Africa NK1/NK3 Receptor Antagonists Sales by Country (2020-2025)
 - 8.1.2 Middle East & Africa NK1/NK3 Receptor Antagonists Revenue by Country (2020-2025)
- 8.2 Middle East & Africa NK1/NK3 Receptor Antagonists Sales by Type (2020-2025)
- 8.3 Middle East & Africa NK1/NK3 Receptor Antagonists Sales by Application (2020-2025)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of NK1/NK3 Receptor Antagonists
- 10.3 Manufacturing Process Analysis of NK1/NK3 Receptor Antagonists
- 10.4 Industry Chain Structure of NK1/NK3 Receptor Antagonists

11 MARKETING, DISTRIBUTORS AND CUSTOMER

- 11.1 Sales Channel
 - 11.1.1 Direct Channels
 - 11.1.2 Indirect Channels
- 11.2 NK1/NK3 Receptor Antagonists Distributors

11.3 NK1/NK3 Receptor Antagonists Customer

12 WORLD FORECAST REVIEW FOR NK1/NK3 RECEPTOR ANTAGONISTS BY GEOGRAPHIC REGION

12.1 Global NK1/NK3 Receptor Antagonists Market Size Forecast by Region

12.1.1 Global NK1/NK3 Receptor Antagonists Forecast by Region (2026-2031)

12.1.2 Global NK1/NK3 Receptor Antagonists Annual Revenue Forecast by Region (2026-2031)

12.2 Americas Forecast by Country (2026-2031)

12.3 APAC Forecast by Region (2026-2031)

12.4 Europe Forecast by Country (2026-2031)

12.5 Middle East & Africa Forecast by Country (2026-2031)

12.6 Global NK1/NK3 Receptor Antagonists Forecast by Type (2026-2031)

12.7 Global NK1/NK3 Receptor Antagonists Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Merck

13.1.1 Merck Company Information

13.1.2 Merck NK1/NK3 Receptor Antagonists Product Portfolios and Specifications

13.1.3 Merck NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)

13.1.4 Merck Main Business Overview

13.1.5 Merck Latest Developments

13.2 Helsinn Healthcare

13.2.1 Helsinn Healthcare Company Information

13.2.2 Helsinn Healthcare NK1/NK3 Receptor Antagonists Product Portfolios and Specifications

13.2.3 Helsinn Healthcare NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)

13.2.4 Helsinn Healthcare Main Business Overview

13.2.5 Helsinn Healthcare Latest Developments

13.3 TerSera Therapeutics

13.3.1 TerSera Therapeutics Company Information

13.3.2 TerSera Therapeutics NK1/NK3 Receptor Antagonists Product Portfolios and Specifications

13.3.3 TerSera Therapeutics NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)

- 13.3.4 TerSera Therapeutics Main Business Overview
- 13.3.5 TerSera Therapeutics Latest Developments
- 13.4 Astellas
 - 13.4.1 Astellas Company Information
 - 13.4.2 Astellas NK1/NK3 Receptor Antagonists Product Portfolios and Specifications
 - 13.4.3 Astellas NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.4.4 Astellas Main Business Overview
 - 13.4.5 Astellas Latest Developments
- 13.5 Bayer
 - 13.5.1 Bayer Company Information
 - 13.5.2 Bayer NK1/NK3 Receptor Antagonists Product Portfolios and Specifications
 - 13.5.3 Bayer NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.5.4 Bayer Main Business Overview
 - 13.5.5 Bayer Latest Developments
- 13.6 Heron Therapeutics
 - 13.6.1 Heron Therapeutics Company Information
 - 13.6.2 Heron Therapeutics NK1/NK3 Receptor Antagonists Product Portfolios and Specifications
 - 13.6.3 Heron Therapeutics NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.6.4 Heron Therapeutics Main Business Overview
 - 13.6.5 Heron Therapeutics Latest Developments
- 13.7 Glenmark
 - 13.7.1 Glenmark Company Information
 - 13.7.2 Glenmark NK1/NK3 Receptor Antagonists Product Portfolios and Specifications
 - 13.7.3 Glenmark NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.7.4 Glenmark Main Business Overview
 - 13.7.5 Glenmark Latest Developments
- 13.8 Torrent Pharmaceuticals
 - 13.8.1 Torrent Pharmaceuticals Company Information
 - 13.8.2 Torrent Pharmaceuticals NK1/NK3 Receptor Antagonists Product Portfolios and Specifications
 - 13.8.3 Torrent Pharmaceuticals NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.8.4 Torrent Pharmaceuticals Main Business Overview
 - 13.8.5 Torrent Pharmaceuticals Latest Developments

13.9 Fresenius Kabi

13.9.1 Fresenius Kabi Company Information

13.9.2 Fresenius Kabi NK1/NK3 Receptor Antagonists Product Portfolios and Specifications

13.9.3 Fresenius Kabi NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)

13.9.4 Fresenius Kabi Main Business Overview

13.9.5 Fresenius Kabi Latest Developments

13.10 Chia Tai Tianqing Pharmaceutical

13.10.1 Chia Tai Tianqing Pharmaceutical Company Information

13.10.2 Chia Tai Tianqing Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolios and Specifications

13.10.3 Chia Tai Tianqing Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)

13.10.4 Chia Tai Tianqing Pharmaceutical Main Business Overview

13.10.5 Chia Tai Tianqing Pharmaceutical Latest Developments

13.11 Qilu Pharmaceutical

13.11.1 Qilu Pharmaceutical Company Information

13.11.2 Qilu Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolios and Specifications

13.11.3 Qilu Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)

13.11.4 Qilu Pharmaceutical Main Business Overview

13.11.5 Qilu Pharmaceutical Latest Developments

13.12 Jiangsu Hengrui Pharmaceuticals

13.12.1 Jiangsu Hengrui Pharmaceuticals Company Information

13.12.2 Jiangsu Hengrui Pharmaceuticals NK1/NK3 Receptor Antagonists Product Portfolios and Specifications

13.12.3 Jiangsu Hengrui Pharmaceuticals NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)

13.12.4 Jiangsu Hengrui Pharmaceuticals Main Business Overview

13.12.5 Jiangsu Hengrui Pharmaceuticals Latest Developments

13.13 Beijing Sihuan Pharmaceutical

13.13.1 Beijing Sihuan Pharmaceutical Company Information

13.13.2 Beijing Sihuan Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolios and Specifications

13.13.3 Beijing Sihuan Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)

13.13.4 Beijing Sihuan Pharmaceutical Main Business Overview

- 13.13.5 Beijing Sihuan Pharmaceutical Latest Developments
- 13.14 Yichang Humanwell Pharmaceutical
 - 13.14.1 Yichang Humanwell Pharmaceutical Company Information
 - 13.14.2 Yichang Humanwell Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolios and Specifications
 - 13.14.3 Yichang Humanwell Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.14.4 Yichang Humanwell Pharmaceutical Main Business Overview
 - 13.14.5 Yichang Humanwell Pharmaceutical Latest Developments
- 13.15 Hansoh Pharma
 - 13.15.1 Hansoh Pharma Company Information
 - 13.15.2 Hansoh Pharma NK1/NK3 Receptor Antagonists Product Portfolios and Specifications
 - 13.15.3 Hansoh Pharma NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.15.4 Hansoh Pharma Main Business Overview
 - 13.15.5 Hansoh Pharma Latest Developments
- 13.16 Luoxin Pharmaceutical
 - 13.16.1 Luoxin Pharmaceutical Company Information
 - 13.16.2 Luoxin Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolios and Specifications
 - 13.16.3 Luoxin Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.16.4 Luoxin Pharmaceutical Main Business Overview
 - 13.16.5 Luoxin Pharmaceutical Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. NK1/NK3 Receptor Antagonists Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & (\$ millions)

Table 2. NK1/NK3 Receptor Antagonists Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & (\$ millions)

Table 3. Major Players of NK1 Receptor Antagonist

Table 4. Major Players of NK3 Receptor Antagonist

Table 5. Major Players of Dual Antagonist

Table 6. Global NK1/NK3 Receptor Antagonists Sales by Type (2020-2025) & (K Units)

Table 7. Global NK1/NK3 Receptor Antagonists Sales Market Share by Type (2020-2025)

Table 8. Global NK1/NK3 Receptor Antagonists Revenue by Type (2020-2025) & (\$ million)

Table 9. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Type (2020-2025)

Table 10. Global NK1/NK3 Receptor Antagonists Sale Price by Type (2020-2025) & (US\$/Unit)

Table 11. Global NK1/NK3 Receptor Antagonists Sale by Application (2020-2025) & (K Units)

Table 12. Global NK1/NK3 Receptor Antagonists Sale Market Share by Application (2020-2025)

Table 13. Global NK1/NK3 Receptor Antagonists Revenue by Application (2020-2025) & (\$ million)

Table 14. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Application (2020-2025)

Table 15. Global NK1/NK3 Receptor Antagonists Sale Price by Application (2020-2025) & (US\$/Unit)

Table 16. Global NK1/NK3 Receptor Antagonists Sales by Company (2020-2025) & (K Units)

Table 17. Global NK1/NK3 Receptor Antagonists Sales Market Share by Company (2020-2025)

Table 18. Global NK1/NK3 Receptor Antagonists Revenue by Company (2020-2025) & (\$ millions)

Table 19. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Company (2020-2025)

Table 20. Global NK1/NK3 Receptor Antagonists Sale Price by Company (2020-2025)

& (US\$/Unit)

Table 21. Key Manufacturers NK1/NK3 Receptor Antagonists Producing Area Distribution and Sales Area

Table 22. Players NK1/NK3 Receptor Antagonists Products Offered

Table 23. NK1/NK3 Receptor Antagonists Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

Table 24. New Products and Potential Entrants

Table 25. Market M&A Activity & Strategy

Table 26. Global NK1/NK3 Receptor Antagonists Sales by Geographic Region (2020-2025) & (K Units)

Table 27. Global NK1/NK3 Receptor Antagonists Sales Market Share Geographic Region (2020-2025)

Table 28. Global NK1/NK3 Receptor Antagonists Revenue by Geographic Region (2020-2025) & (\$ millions)

Table 29. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Geographic Region (2020-2025)

Table 30. Global NK1/NK3 Receptor Antagonists Sales by Country/Region (2020-2025) & (K Units)

Table 31. Global NK1/NK3 Receptor Antagonists Sales Market Share by Country/Region (2020-2025)

Table 32. Global NK1/NK3 Receptor Antagonists Revenue by Country/Region (2020-2025) & (\$ millions)

Table 33. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Country/Region (2020-2025)

Table 34. Americas NK1/NK3 Receptor Antagonists Sales by Country (2020-2025) & (K Units)

Table 35. Americas NK1/NK3 Receptor Antagonists Sales Market Share by Country (2020-2025)

Table 36. Americas NK1/NK3 Receptor Antagonists Revenue by Country (2020-2025) & (\$ millions)

Table 37. Americas NK1/NK3 Receptor Antagonists Sales by Type (2020-2025) & (K Units)

Table 38. Americas NK1/NK3 Receptor Antagonists Sales by Application (2020-2025) & (K Units)

Table 39. APAC NK1/NK3 Receptor Antagonists Sales by Region (2020-2025) & (K Units)

Table 40. APAC NK1/NK3 Receptor Antagonists Sales Market Share by Region (2020-2025)

Table 41. APAC NK1/NK3 Receptor Antagonists Revenue by Region (2020-2025) & (\$

millions)

Table 42. APAC NK1/NK3 Receptor Antagonists Sales by Type (2020-2025) & (K Units)

Table 43. APAC NK1/NK3 Receptor Antagonists Sales by Application (2020-2025) & (K Units)

Table 44. Europe NK1/NK3 Receptor Antagonists Sales by Country (2020-2025) & (K Units)

Table 45. Europe NK1/NK3 Receptor Antagonists Revenue by Country (2020-2025) & (\$ millions)

Table 46. Europe NK1/NK3 Receptor Antagonists Sales by Type (2020-2025) & (K Units)

Table 47. Europe NK1/NK3 Receptor Antagonists Sales by Application (2020-2025) & (K Units)

Table 48. Middle East & Africa NK1/NK3 Receptor Antagonists Sales by Country (2020-2025) & (K Units)

Table 49. Middle East & Africa NK1/NK3 Receptor Antagonists Revenue Market Share by Country (2020-2025)

Table 50. Middle East & Africa NK1/NK3 Receptor Antagonists Sales by Type (2020-2025) & (K Units)

Table 51. Middle East & Africa NK1/NK3 Receptor Antagonists Sales by Application (2020-2025) & (K Units)

Table 52. Key Market Drivers & Growth Opportunities of NK1/NK3 Receptor Antagonists

Table 53. Key Market Challenges & Risks of NK1/NK3 Receptor Antagonists

Table 54. Key Industry Trends of NK1/NK3 Receptor Antagonists

Table 55. NK1/NK3 Receptor Antagonists Raw Material

Table 56. Key Suppliers of Raw Materials

Table 57. NK1/NK3 Receptor Antagonists Distributors List

Table 58. NK1/NK3 Receptor Antagonists Customer List

Table 59. Global NK1/NK3 Receptor Antagonists Sales Forecast by Region (2026-2031) & (K Units)

Table 60. Global NK1/NK3 Receptor Antagonists Revenue Forecast by Region (2026-2031) & (\$ millions)

Table 61. Americas NK1/NK3 Receptor Antagonists Sales Forecast by Country (2026-2031) & (K Units)

Table 62. Americas NK1/NK3 Receptor Antagonists Annual Revenue Forecast by Country (2026-2031) & (\$ millions)

Table 63. APAC NK1/NK3 Receptor Antagonists Sales Forecast by Region (2026-2031) & (K Units)

Table 64. APAC NK1/NK3 Receptor Antagonists Annual Revenue Forecast by Region

(2026-2031) & (\$ millions)

Table 65. Europe NK1/NK3 Receptor Antagonists Sales Forecast by Country

(2026-2031) & (K Units)

Table 66. Europe NK1/NK3 Receptor Antagonists Revenue Forecast by Country

(2026-2031) & (\$ millions)

Table 67. Middle East & Africa NK1/NK3 Receptor Antagonists Sales Forecast by Country (2026-2031) & (K Units)

Table 68. Middle East & Africa NK1/NK3 Receptor Antagonists Revenue Forecast by Country (2026-2031) & (\$ millions)

Table 69. Global NK1/NK3 Receptor Antagonists Sales Forecast by Type (2026-2031) & (K Units)

Table 70. Global NK1/NK3 Receptor Antagonists Revenue Forecast by Type (2026-2031) & (\$ millions)

Table 71. Global NK1/NK3 Receptor Antagonists Sales Forecast by Application (2026-2031) & (K Units)

Table 72. Global NK1/NK3 Receptor Antagonists Revenue Forecast by Application (2026-2031) & (\$ millions)

Table 73. Merck Basic Information, NK1/NK3 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors

Table 74. Merck NK1/NK3 Receptor Antagonists Product Portfolios and Specifications

Table 75. Merck NK1/NK3 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2025)

Table 76. Merck Main Business

Table 77. Merck Latest Developments

Table 78. Helsinn Healthcare Basic Information, NK1/NK3 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors

Table 79. Helsinn Healthcare NK1/NK3 Receptor Antagonists Product Portfolios and Specifications

Table 80. Helsinn Healthcare NK1/NK3 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2025)

Table 81. Helsinn Healthcare Main Business

Table 82. Helsinn Healthcare Latest Developments

Table 83. TerSera Therapeutics Basic Information, NK1/NK3 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors

Table 84. TerSera Therapeutics NK1/NK3 Receptor Antagonists Product Portfolios and Specifications

Table 85. TerSera Therapeutics NK1/NK3 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2025)

Table 86. TerSera Therapeutics Main Business

- Table 87. TerSera Therapeutics Latest Developments
- Table 88. Astellas Basic Information, NK1/NK3 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
- Table 89. Astellas NK1/NK3 Receptor Antagonists Product Portfolios and Specifications
- Table 90. Astellas NK1/NK3 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2025)
- Table 91. Astellas Main Business
- Table 92. Astellas Latest Developments
- Table 93. Bayer Basic Information, NK1/NK3 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
- Table 94. Bayer NK1/NK3 Receptor Antagonists Product Portfolios and Specifications
- Table 95. Bayer NK1/NK3 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2025)
- Table 96. Bayer Main Business
- Table 97. Bayer Latest Developments
- Table 98. Heron Therapeutics Basic Information, NK1/NK3 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
- Table 99. Heron Therapeutics NK1/NK3 Receptor Antagonists Product Portfolios and Specifications
- Table 100. Heron Therapeutics NK1/NK3 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2025)
- Table 101. Heron Therapeutics Main Business
- Table 102. Heron Therapeutics Latest Developments
- Table 103. Glenmark Basic Information, NK1/NK3 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
- Table 104. Glenmark NK1/NK3 Receptor Antagonists Product Portfolios and Specifications
- Table 105. Glenmark NK1/NK3 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2025)
- Table 106. Glenmark Main Business
- Table 107. Glenmark Latest Developments
- Table 108. Torrent Pharmaceuticals Basic Information, NK1/NK3 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
- Table 109. Torrent Pharmaceuticals NK1/NK3 Receptor Antagonists Product Portfolios and Specifications
- Table 110. Torrent Pharmaceuticals NK1/NK3 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2025)
- Table 111. Torrent Pharmaceuticals Main Business
- Table 112. Torrent Pharmaceuticals Latest Developments

Table 113. Fresenius Kabi Basic Information, NK1/NK3 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors

Table 114. Fresenius Kabi NK1/NK3 Receptor Antagonists Product Portfolios and Specifications

Table 115. Fresenius Kabi NK1/NK3 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2025)

Table 116. Fresenius Kabi Main Business

Table 117. Fresenius Kabi Latest Developments

Table 118. Chia Tai Tianqing Pharmaceutical Basic Information, NK1/NK3 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors

Table 119. Chia Tai Tianqing Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolios and Specifications

Table 120. Chia Tai Tianqing Pharmaceutical NK1/NK3 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2025)

Table 121. Chia Tai Tianqing Pharmaceutical Main Business

Table 122. Chia Tai Tianqing Pharmaceutical Latest Developments

Table 123. Qilu Pharmaceutical Basic Information, NK1/NK3 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors

Table 124. Qilu Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolios and Specifications

Table 125. Qilu Pharmaceutical NK1/NK3 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2025)

Table 126. Qilu Pharmaceutical Main Business

Table 127. Qilu Pharmaceutical Latest Developments

Table 128. Jiangsu Hengrui Pharmaceuticals Basic Information, NK1/NK3 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors

Table 129. Jiangsu Hengrui Pharmaceuticals NK1/NK3 Receptor Antagonists Product Portfolios and Specifications

Table 130. Jiangsu Hengrui Pharmaceuticals NK1/NK3 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2025)

Table 131. Jiangsu Hengrui Pharmaceuticals Main Business

Table 132. Jiangsu Hengrui Pharmaceuticals Latest Developments

Table 133. Beijing Sihuan Pharmaceutical Basic Information, NK1/NK3 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors

Table 134. Beijing Sihuan Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolios and Specifications

Table 135. Beijing Sihuan Pharmaceutical NK1/NK3 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2025)

Table 136. Beijing Sihuan Pharmaceutical Main Business

- Table 137. Beijing Sihuan Pharmaceutical Latest Developments
- Table 138. Yichang Humanwell Pharmaceutical Basic Information, NK1/NK3 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
- Table 139. Yichang Humanwell Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolios and Specifications
- Table 140. Yichang Humanwell Pharmaceutical NK1/NK3 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2025)
- Table 141. Yichang Humanwell Pharmaceutical Main Business
- Table 142. Yichang Humanwell Pharmaceutical Latest Developments
- Table 143. Hansoh Pharma Basic Information, NK1/NK3 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
- Table 144. Hansoh Pharma NK1/NK3 Receptor Antagonists Product Portfolios and Specifications
- Table 145. Hansoh Pharma NK1/NK3 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2025)
- Table 146. Hansoh Pharma Main Business
- Table 147. Hansoh Pharma Latest Developments
- Table 148. Luoxin Pharmaceutical Basic Information, NK1/NK3 Receptor Antagonists Manufacturing Base, Sales Area and Its Competitors
- Table 149. Luoxin Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolios and Specifications
- Table 150. Luoxin Pharmaceutical NK1/NK3 Receptor Antagonists Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2025)
- Table 151. Luoxin Pharmaceutical Main Business
- Table 152. Luoxin Pharmaceutical Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of NK1/NK3 Receptor Antagonists

Figure 2. NK1/NK3 Receptor Antagonists Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global NK1/NK3 Receptor Antagonists Sales Growth Rate 2020-2031 (K Units)

Figure 7. Global NK1/NK3 Receptor Antagonists Revenue Growth Rate 2020-2031 (\$ millions)

Figure 8. NK1/NK3 Receptor Antagonists Sales by Geographic Region (2020, 2024 & 2031) & (\$ millions)

Figure 9. NK1/NK3 Receptor Antagonists Sales Market Share by Country/Region (2024)

Figure 10. NK1/NK3 Receptor Antagonists Sales Market Share by Country/Region (2020, 2024 & 2031)

Figure 11. Product Picture of NK1 Receptor Antagonist

Figure 12. Product Picture of NK3 Receptor Antagonist

Figure 13. Product Picture of Dual Antagonist

Figure 14. Global NK1/NK3 Receptor Antagonists Sales Market Share by Type in 2025

Figure 15. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Type (2020-2025)

Figure 16. NK1/NK3 Receptor Antagonists Consumed in Hospital

Figure 17. Global NK1/NK3 Receptor Antagonists Market: Hospital (2020-2025) & (K Units)

Figure 18. NK1/NK3 Receptor Antagonists Consumed in Specialty Clinic

Figure 19. Global NK1/NK3 Receptor Antagonists Market: Specialty Clinic (2020-2025) & (K Units)

Figure 20. Global NK1/NK3 Receptor Antagonists Sale Market Share by Application (2024)

Figure 21. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Application in 2025

Figure 22. NK1/NK3 Receptor Antagonists Sales by Company in 2025 (K Units)

Figure 23. Global NK1/NK3 Receptor Antagonists Sales Market Share by Company in 2025

Figure 24. NK1/NK3 Receptor Antagonists Revenue by Company in 2025 (\$ millions)

Figure 25. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Company in 2025

Figure 26. Global NK1/NK3 Receptor Antagonists Sales Market Share by Geographic Region (2020-2025)

Figure 27. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Geographic Region in 2025

Figure 28. Americas NK1/NK3 Receptor Antagonists Sales 2020-2025 (K Units)

Figure 29. Americas NK1/NK3 Receptor Antagonists Revenue 2020-2025 (\$ millions)

Figure 30. APAC NK1/NK3 Receptor Antagonists Sales 2020-2025 (K Units)

Figure 31. APAC NK1/NK3 Receptor Antagonists Revenue 2020-2025 (\$ millions)

Figure 32. Europe NK1/NK3 Receptor Antagonists Sales 2020-2025 (K Units)

Figure 33. Europe NK1/NK3 Receptor Antagonists Revenue 2020-2025 (\$ millions)

Figure 34. Middle East & Africa NK1/NK3 Receptor Antagonists Sales 2020-2025 (K Units)

Figure 35. Middle East & Africa NK1/NK3 Receptor Antagonists Revenue 2020-2025 (\$ millions)

Figure 36. Americas NK1/NK3 Receptor Antagonists Sales Market Share by Country in 2025

Figure 37. Americas NK1/NK3 Receptor Antagonists Revenue Market Share by Country (2020-2025)

Figure 38. Americas NK1/NK3 Receptor Antagonists Sales Market Share by Type (2020-2025)

Figure 39. Americas NK1/NK3 Receptor Antagonists Sales Market Share by Application (2020-2025)

Figure 40. United States NK1/NK3 Receptor Antagonists Revenue Growth 2020-2025 (\$ millions)

Figure 41. Canada NK1/NK3 Receptor Antagonists Revenue Growth 2020-2025 (\$ millions)

Figure 42. Mexico NK1/NK3 Receptor Antagonists Revenue Growth 2020-2025 (\$ millions)

Figure 43. Brazil NK1/NK3 Receptor Antagonists Revenue Growth 2020-2025 (\$ millions)

Figure 44. APAC NK1/NK3 Receptor Antagonists Sales Market Share by Region in 2025

Figure 45. APAC NK1/NK3 Receptor Antagonists Revenue Market Share by Region (2020-2025)

Figure 46. APAC NK1/NK3 Receptor Antagonists Sales Market Share by Type (2020-2025)

Figure 47. APAC NK1/NK3 Receptor Antagonists Sales Market Share by Application

(2020-2025)

Figure 48. China NK1/NK3 Receptor Antagonists Revenue Growth 2020-2025 (\$ millions)

Figure 49. Japan NK1/NK3 Receptor Antagonists Revenue Growth 2020-2025 (\$ millions)

Figure 50. South Korea NK1/NK3 Receptor Antagonists Revenue Growth 2020-2025 (\$ millions)

Figure 51. Southeast Asia NK1/NK3 Receptor Antagonists Revenue Growth 2020-2025 (\$ millions)

Figure 52. India NK1/NK3 Receptor Antagonists Revenue Growth 2020-2025 (\$ millions)

Figure 53. Australia NK1/NK3 Receptor Antagonists Revenue Growth 2020-2025 (\$ millions)

Figure 54. China Taiwan NK1/NK3 Receptor Antagonists Revenue Growth 2020-2025 (\$ millions)

Figure 55. Europe NK1/NK3 Receptor Antagonists Sales Market Share by Country in 2025

Figure 56. Europe NK1/NK3 Receptor Antagonists Revenue Market Share by Country (2020-2025)

Figure 57. Europe NK1/NK3 Receptor Antagonists Sales Market Share by Type (2020-2025)

Figure 58. Europe NK1/NK3 Receptor Antagonists Sales Market Share by Application (2020-2025)

Figure 59. Germany NK1/NK3 Receptor Antagonists Revenue Growth 2020-2025 (\$ millions)

Figure 60. France NK1/NK3 Receptor Antagonists Revenue Growth 2020-2025 (\$ millions)

Figure 61. UK NK1/NK3 Receptor Antagonists Revenue Growth 2020-2025 (\$ millions)

Figure 62. Italy NK1/NK3 Receptor Antagonists Revenue Growth 2020-2025 (\$ millions)

Figure 63. Russia NK1/NK3 Receptor Antagonists Revenue Growth 2020-2025 (\$ millions)

Figure 64. Middle East & Africa NK1/NK3 Receptor Antagonists Sales Market Share by Country (2020-2025)

Figure 65. Middle East & Africa NK1/NK3 Receptor Antagonists Sales Market Share by Type (2020-2025)

Figure 66. Middle East & Africa NK1/NK3 Receptor Antagonists Sales Market Share by Application (2020-2025)

Figure 67. Egypt NK1/NK3 Receptor Antagonists Revenue Growth 2020-2025 (\$ millions)

Figure 68. South Africa NK1/NK3 Receptor Antagonists Revenue Growth 2020-2025 (\$ millions)

Figure 69. Israel NK1/NK3 Receptor Antagonists Revenue Growth 2020-2025 (\$ millions)

Figure 70. Turkey NK1/NK3 Receptor Antagonists Revenue Growth 2020-2025 (\$ millions)

Figure 71. GCC Countries NK1/NK3 Receptor Antagonists Revenue Growth 2020-2025 (\$ millions)

Figure 72. Manufacturing Cost Structure Analysis of NK1/NK3 Receptor Antagonists in 2025

Figure 73. Manufacturing Process Analysis of NK1/NK3 Receptor Antagonists

Figure 74. Industry Chain Structure of NK1/NK3 Receptor Antagonists

Figure 75. Channels of Distribution

Figure 76. Global NK1/NK3 Receptor Antagonists Sales Market Forecast by Region (2026-2031)

Figure 77. Global NK1/NK3 Receptor Antagonists Revenue Market Share Forecast by Region (2026-2031)

Figure 78. Global NK1/NK3 Receptor Antagonists Sales Market Share Forecast by Type (2026-2031)

Figure 79. Global NK1/NK3 Receptor Antagonists Revenue Market Share Forecast by Type (2026-2031)

Figure 80. Global NK1/NK3 Receptor Antagonists Sales Market Share Forecast by Application (2026-2031)

Figure 81. Global NK1/NK3 Receptor Antagonists Revenue Market Share Forecast by Application (2026-2031)

I would like to order

Product name: Global NK1/NK3 Receptor Antagonists Market Growth 2025-2031

Product link: <https://marketpublishers.com/r/G97DAD25310BEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G97DAD25310BEN.html>